Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: Evidence from clinic to laboratory

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 866-876

  Liu, Lei ^a   Li, Jian ^a   Zhang, Yan ^a   Zhang, Shenghui ^a   Ye, Jianqin ^a   Wen, Zhichao ^a   Ding, Jianping ^b   Kunapuli, Satya P ^c   Luo, Xinping ^a   Ding, Zhongren ^a  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute coronary syndrome; antiplatelet; P2Y12 receptor antagonist; phosphodiesterase inhibitor; salvianolate

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; ATORVASTATIN; CALCIUM ION; CLOPIDOGREL; COLLAGEN; DUAL SPECIFICITY PHOSPHATASE 2; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; PHOSPHODIESTERASE; PURINERGIC P2Y12 RECEPTOR; SALVIANOLIC ACID B; THROMBIN; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; BENZOFURAN DERIVATIVE; HERBACEOUS AGENT; PHOSPHODIESTERASE INHIBITOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATOMIC FORCE MICROSCOPY; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION ASSAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; SALVIA MILTIORRHIZA; THROMBOCYTE;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; BENZOFURANS; BLOOD PLATELETS; DRUGS, CHINESE HERBAL; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SALVIA MILTIORRHIZA; TICLOPIDINE;

EID: 84908219741     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.07.019     Document Type: Article

References (38)

1. Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol 2008;28:s33-8.
2. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207-14.
3. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A Randomized, Double- Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions Results From the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) Trial. J Am Coll Cardiol 2011;57:1264-70.
4. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011;57:280-9.
5. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005;46:1833-7.
6. Li X, Yu C, Sun W, Liu G, Jia J, Wang Y. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2004;18:2878-82.
7. Huang ZS, Zeng CL, Zhu LJ, Jiang L, Li N, Hu H. Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase. J Thromb Haemost 2010;8:1383-93.
8. Ma C, Yao Y, Yue QX, Zhou XW, Yang PY, Wu WY, et al. Differential proteomic analysis of platelets suggested possible signal cascades network in platelets treated with salvianolic acid B. PLoS One 2011;6:e14692.
9. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
10. Labios M, Martinez M, Gabriel F, Gomez-Biedma S, Guiral V, Vivo M, et al. Flow cytometric analysis of platelet activation in hypertensive patients. Effect of doxazosin. Thromb Res 2003;110:203-8.
11. Hu L, Fan Z, Du H, Ni R, Zhang S, Yin K, et al. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y(1)(2) receptor and phosphodiesterase. Thromb Haemost 2011;106:1203-14.
12. Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, et al. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 2010;104:845-57.
13. Zhang SH, Zhang Y, Shen J, Zhang S, Chen L, Gu J, et al. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase. J Thromb Haemost 2013;11:1855-66.
14. Shankar H, Murugappan S, Kim S, Jin J, Ding Z, Wickman K, et al. Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood 2004;104:1335-43.
15. Merritt JE, McCarthy SA, Davies MP, Moores KE. Use of fluo-3 to measure cytosolic Ca2+ in platelets and neutrophils. Loading cells with the dye, calibration of traces, measurements in the presence of plasma, and buffering of cytosolic Ca2+. Biochem J 1990;269:513-9.
16. Yamamoto H, Takahashi K, Watanabe H, Yoshikawa Y, Shirakawa R, Higashi T, et al. Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ J 2008;72:1844-51.
17. Wentworth JK, Pula G, Poole AW. Vasodilator-stimulated phosphoprotein (VASP) is phosphorylated on Ser157 by protein kinase C-dependent and -independent mechanisms in thrombin-stimulated human platelets. Biochem J 2006;393:555-64.
18. Zhang J, Lu H, Gu W, Wu N, Zhou K, Hu Y, et al. Earlymixed farming of millet and rice 7800 years ago in the Middle Yellow River region, China. PLoS One 2012;7:e52146.
19. Ding ZR, Huang SJ, Sun JJ. Induction of platelet activation by cobra venomfactor from Naja naja atra in rat. Acta Pharmacol Sin 2000;21:649-54.
20. Spoto G, Whitehead E, Ferraro A, Di Terlizzi PM, Turano C, Riva F. A reverse-phase HPLC method for cAMP phosphodiesterase activity. Anal Biochem 1991;196:207-10.
21. Su X, Mi J, Yan J, Flevaris P, Lu Y, Liu H, et al. RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outsidein signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood 2008;112:592-602.
22. Pan C, Wei X, Ye J, Liu G, Zhang S, Zhang Y, et al. BF066, a novel dual target antiplatelet agent without significant bleeding. PLoS One 2012;7:e40451.
23. Wu YT, Chen YF, Hsieh YJ, Jaw I, Shiao MS, Tsai TH. Bioavailability of salvianolic acid B in conscious and freely moving rats. Int J Pharm 2006;326:25-31.
24. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340-5.
25. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A 1998;95:8070-4.
26. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-7.
27. Cattaneo M. The clinical relevance of response variability to antiplatelet therapy. Hematol Am Soc Hematol Educ Program 2011;2011:70-5.
28. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92.
29. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2 T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925-34.
30. Becker RC, Gibson CM, Jennings LK, Morrow DA. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. Am J Cardiol 2010;106:S2-3.
31. Valgimigli M, Minarelli M. Triple antiplatelet therapy in acute coronary syndromes. Drugs 2011;71:1703-19.
32. Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr Opin Cell Biol 1994;6:695-704.
33. Wu YP, Zhao XM, Pan SD, Guo de A, Wei R, Han JJ, et al. Salvianolic acid B inhibits platelet adhesion under conditions of flow by a mechanism involving the collagen receptor alpha2beta1. Thromb Res 2008;123:298-305.
34. Yao Y, Wu WY, Liu AH, Deng SS, Bi KS, Liu X, et al. Interaction of salvianolic acids and notoginsengnosides in inhibition of ADP-induced platelet aggregation. Am J Chin Med 2008;36:313-28.
35. Li X, Yu C, Lu Y, Gu Y, Lu J, Xu W, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats. Drug Metab Dispos 2007;35:234-9.
36. Wang Z, Roberts JM, Grant PG, Colman RW, Schreiber AD. The effect of a medicinal Chinese herb on platelet function. Thromb Haemost 1982;48:301-6.
37. Geng DF, Liu M, Jin DM, Wu W, Deng J, Wang JF. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology 2012;122:148-57.
38. Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, et al. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol 2009;68:4-13.